Advertisement
Short Report| Volume 53, 103620, February 2023

Fetal outcomes with and without the use of sugammadex in pregnant patients undergoing non-obstetric surgery: a multicenter retrospective study

  • Author Footnotes
    1 SN and HI contributed equally to the article.
    S. Noguchi
    Footnotes
    1 SN and HI contributed equally to the article.
    Affiliations
    Department of Obstetric Anesthesiology, Center for Maternal-Fetal and Neonatal Medicine, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
    Search for articles by this author
  • Author Footnotes
    1 SN and HI contributed equally to the article.
    H. Iwasaki
    Footnotes
    1 SN and HI contributed equally to the article.
    Affiliations
    Department of Anesthesiology, Nihon University School of Medicine, Tokyo, Japan
    Search for articles by this author
  • Y. Shiko
    Affiliations
    Department of Anesthesiology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan

    Biostatistics Section, Clinical Research Center, Chiba University Hospital, Chiba, Japan
    Search for articles by this author
  • Y. Kawasaki
    Affiliations
    Department of Anesthesiology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan

    Faculty of Nursing, Japanese Red Cross College of Nursing, Tokyo, Japan
    Search for articles by this author
  • Y. Ishida
    Affiliations
    Department of Anesthesiology, Seirei Hamamatsu General Hospital, Shizuoka, Japan
    Search for articles by this author
  • S. Shinomiya
    Affiliations
    Department of Anesthesiology, Chibune General Hospital, Osaka, Japan
    Search for articles by this author
  • R. Ono Uokawa
    Affiliations
    Department of Anesthesiology, Chibune General Hospital, Osaka, Japan
    Search for articles by this author
  • Y. Mazda
    Correspondence
    Correspondence to: Yusuke Mazda, Department of Obstetric Anesthesiology, Center for Maternal-Fetal and Neonatal Medicine, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan. Fax: +81 49 226 2237.
    Affiliations
    Department of Obstetric Anesthesiology, Center for Maternal-Fetal and Neonatal Medicine, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
    Search for articles by this author
  • Author Footnotes
    1 SN and HI contributed equally to the article.
Published:December 22, 2022DOI:https://doi.org/10.1016/j.ijoa.2022.103620

      Highlights

      • Seventy-three pregnant women received sugammadex in non-obstetric surgery.
      • Sugammadex was not associated with miscarriage or preterm labor within four weeks.
      • Missing data may have obscured potential adverse outcomes from sugammadex exposure.
      • The findings do not exclude sugammadex-related adverse pregnancy outcomes.

      Abstract

      Background

      The influence of sugammadex exposure during pregnancy on progesterone withdrawal and miscarriage is unknown. We aimed to compare the fetal outcomes in pregnant patients who had undergone non-obstetric surgery with and without sugammadex.

      Methods

      We retrospectively reviewed the medical charts of pregnant women who underwent non-obstetric surgery at three tertiary perinatal care centers in Japan from January 2013 to December 2020. The women were divided into those who received general anesthesia with sugammadex (GA with SGX) and those who received general anesthesia without sugammadex (GA without SGX). We compared miscarriages and preterm births within four weeks after surgery.

      Results

      Among the 124 women, 73 and 51 were included in the GA with SGX and GA without SGX groups, respectively. The two groups showed no differences in the rate of miscarriages or preterm births (3.0 % vs 4.3 %; odds ratio 1.42, 95 % confidence interval 0.19 to 10.47; P = 1.00). The SGX and no SGX groups were missing outcomes for 8.2 % and 7.8 % of cases, respectively.

      Conclusions

      Having GA with SGX or GA without SGX did not result in different rates of miscarriage or preterm birth within four weeks after the procedure. These findings do not exclude a potential association between sugammadex exposure during pregnancy and adverse pregnancy outcomes. Missing data may have obscured possible adverse outcomes from sugammadex exposure.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Obstetric Anesthesia
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bom A.
        • Bradley M.
        • Cameron K.
        • et al.
        A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host.
        Angew Chem Int Ed Engl. 2002; 41: 266-270
      1. US Food and Drug Administration. Prescribing Information. Bridion (sugammadex). https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022225lbl.pdf. Accessed February 3, 2022.

        • Et T.
        • Topal A.
        • Erol A.
        • Tavlan A.
        • Kılıçaslan A.
        • Uzun S.T.
        The effects of sugammadex on progesterone levels in pregnant rats.
        Balkan Med J. 2015; 32: 203-207https://doi.org/10.5152/balkanmedj.2015.15502
        • Peplow P.V.
        Effects of progesterone withdrawal on uterine prostaglandin levels in the ovariectomized pregnant rat.
        Prostaglandins Leukot Essent Fatty Acids. 1991; 44: 259-261https://doi.org/10.1016/0952-3278(91)90028-4
        • Bennett J.P.
        • Vallance D.K.
        • Vickery B.H.
        The synchronization of ovulation in the adult female rat by oral administration of megestrol acetate.
        J Reprod Fertil. 1968; 16: 159-163https://doi.org/10.1530/jrf.0.0160159
      2. Willet AW BA, Togioka B, Bensadigh B, Hofer J, Zakowski M. Society for Obstetric Anesthesia and Perinatology Statement on sugammadex during pregnancy and location. April 22, 2019. https://www.soap.org/assets/docs/SOAP_Statement_Sugammadex_During_Pregnancy_Lactation_APPROVED.pdf. Accessed February 3, 2022.

        • Miyazaki Y.
        • Sunaga H.
        • Kida K.
        • et al.
        Incidence of anaphylaxis associated with sugammadex.
        Anesth Analg. 2018; 126: 1505-1508https://doi.org/10.1213/ane.0000000000002562
        • Gunduz Gul G.
        • Ozer A.B.
        • Demirel I.
        • Aksu A.
        • Erhan O.L.
        The effect of sugammadex on steroid hormones: A randomized clinical study.
        J Clin Anesth. 2016; 34: 62-67https://doi.org/10.1016/j.jclinane.2016.03.039
        • Singh S.
        • Klumpner T.T.
        • Pancaro C.
        • Rajala B.
        • Kountanis J.A.
        Sugammadex administration in pregnant women: A case series of maternal and fetal outcomes.
        A A Pract. 2021; 15: e01407
        • Torres S.M.
        • Duarte D.F.
        • Glória A.S.
        • et al.
        Sugammadex administration in pregnant patients undergoing non-obstetric surgery: a case series.
        Braz J Anesthesiol. 2022; 72: 525-528https://doi.org/10.1016/j.bjane.2021.07.034
        • Karahan M.A.
        • Büyükfırat E.
        • Binici O.
        • et al.
        The effects of rocuronium-sugammadex on fetomaternal outcomes in pregnancy undergoing electroconvulsive therapy: A retrospective case series and literature review.
        Cureus. 2019; 11: e4820